Vap'brèves offers you your flash e-cigarette news for the day of Monday, June 27, 2016. (News update at 21:53 a.m.)
UK |
THE E-CIGARETTE INDUSTRY WANTS TO REDISCUTE FROM TPD AFTER BREXIT. |
An e-cigarette industry body is seeking to launch talks with the government on whether the EU tobacco directive can be renegotiated following the Brexit vote.See article) |
UNITED STATES |
STUDY ACCUSED OF INFERRED SPEECHES IN THE E-CIG MARKET |
If we often tend to speak of disinformation for studies that are against the e-cigarette, we will not be surprised to see today a study that turns the situation around. Indeed, researchers at Ohio State University say that prior to FDA regulation, many unproven health claims may have circulated on e-cigarettes and the misinformation could have a lingering effect on consumers. (See article) |
FRANCE |
THE E-CIGARETTE IS A CIGARETTE AS THE OTHERS. |
Retailers of e-cigarettes are not subject to the regulations applicable to tobacconists. Opening a tobacconist is highly regulated. In the first place, the establishment of an establishment is not free, this activity constituting a monopoly of the State. (See article) |
GREECE |
KONSTANTINOS FARSALINOS RELEASES ITS ANALYSIS OF THE EUROBAROMETER 2015 |
He had announced it during the last Vapexpo, the Greek cardiologist plunged with his team in the detailed figures of the 2015 Eurobarometer. While the original statistical report remained very pessimistic about the interest of the electronic cigarette for the smoking population, this new analysis provides a very contrasting light with the official conclusions. (See article) |
GERMANY |
IQOS DE MARLBORO MARKETS THIS MONDAY. |
Tested for sale in Switzerland since last August while being protected from competition from vaping with nicotine by the federal authorities, the "heated-not-burned" tobacco cigarette by Philip Morris plays on the aesthetic imitation of steam mods to recover a lost clientele (See article) |
SWITZERLAND |
AMOUNTS PAID TO PHARMA DOCTORS BY PHARMA ARE KNOWN. |
Sums paid to doctors by the pharmaceutical sector will be known. This is a good start, even if transparency has not yet been achieved by far. (See the video) |